Purpose: We evaluated bladder reservoir function in children with monosymptomatic nocturnal enuresis with and without response to desmopressin, and assessed the importance of first morning voiding when defining maximum voided volume.

Materials And Methods: A total of 238 patients 5 to 15 years old with monosymptomatic nocturnal enuresis completed 2 weeks of enuresis recordings and 4 days of frequency-volume charts. Of the patients 186 completed subsequent home recordings during titration with desmopressin. Maximum voided volumes with and without the first morning void were calculated. Desmopressin response was defined as greater than 50% reduction in wet nights. Maximum voided volume with and without first morning voiding was evaluated as a prognostic factor for desmopressin response.

Results: Mean ± SD maximum voided volume without first morning void was comparable between desmopressin responders and nonresponders (230.5 ± 69.3 ml and 219.0 ± 84.8 ml, respectively, p = 0.391). Inclusion of the first morning void demonstrated responders to have significantly larger values than nonresponders (mean ± SD 296.0 ± 94.0 ml vs 233.5 ± 90.0 ml, p <0.001). When first morning void was included, desmopressin response was seen in 40% of patients with voided volumes of 65% expected volume for age vs 10% of patients with volumes less than 65% expected volume for age.

Conclusions: Maximum voided volume can be used as a predictor of desmopressin response only if first morning voids are taken into consideration. All patients with monosymptomatic nocturnal enuresis should receive clear instructions to include this measure when completing frequency-volume charts.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.juro.2011.10.014DOI Listing

Publication Analysis

Top Keywords

maximum voided
20
monosymptomatic nocturnal
12
nocturnal enuresis
12
morning void
12
morning voiding
8
voided volume
8
volume morning
8
maximum
5
voided
5
desmopressin
5

Similar Publications

Purpose: To compare voiding parameters in women with and without increased postvoid residual (PVR) volume, to correlate these parameters with PVR volume and PVR percentage, and to describe their ability to predict an increased PVR volume.

Methods: Retrospective cross-sectional study of urodynamics data prospectively acquired from consecutive symptomatic women over a 5-year period. Patients with spinal cord disorders and with abdominal straining during voiding (abdominal pressure ≥10 cm H2O over baseline at maximum flow rate [Qmax]) were excluded.

View Article and Find Full Text PDF

Purpose: We aimed to assess the clinical efficacy and safety of combining silodosin and solifenacin for overactive bladder (OAB) in females.

Methods: A retrospective analysis of 586 females with OAB was conducted. Patients received either combination therapy (silodosin 8 mg + solifenacin 5 mg) or monotherapy (solifenacin 5 mg) for 12 weeks.

View Article and Find Full Text PDF

Primary bladder neck obstruction in females: Case series from the Indonesian population.

Int J Surg Case Rep

December 2024

Department of Urology, Faculty of Medicine, Airlangga University, Dr. Soetomo General Academic Hospital, Surabaya, Indonesia.

Introduction: Primary bladder neck obstruction (PBNO) is a rare but significant cause of BOO and LUTS in females, with unclear etiology involving theories of fibrotic narrowing, tissue hyperplasia, or muscle abnormalities. Due to nonspecific symptoms, PBNO diagnosis remains challenging, and optimal surgical treatment needs to be better defined.

Case Presentation: We report two cases of females in their 50s with recurrent urinary retention managed by indwelling catheters.

View Article and Find Full Text PDF

Objective: To assess the available evidence of non-invasive or minimally invasive neuromodulation therapies in improving urodynamic outcomes, voiding diaries, and quality of life in patients with neurogenic lower urinary tract dysfunction (NLUTD) after spinal cord injury (SCI).

Data Sources: A comprehensive search of 10 databases from inception until August 30, 2023 was conducted.

Study Selection: Randomized controlled trials (RCTs) assessing the effects of conventional treatment (CT) and CT combined with sham stimulation (SS), transcranial magnetic stimulation (TMS), sacral nerve magnetic stimulation (SNMS), TMS+SNMS, sacral pulsed electromagnetic field therapy (SPEMFT), sacral transcutaneous electrical nerve stimulation (STENS), sacral dermatomal transcutaneous electrical nerve stimulation (SDTENS), bladder & sacral transcutaneous electrical nerve stimulation (B&STENS), transcutaneous tibial nerve stimulation (TTNS), transcutaneous electrical acupoint stimulation (TEAS), pelvic floor electrical stimulation (PFES), or pelvic floor biofeedback therapy (PFBFBT) on postvoid residual volume (PVR), maximum cystometric capacity (MCC), number of voids per 24 h (V24), mean urine volume per micturition, (MUV), maximum urinary flow rate (Qmax), maximum detrusor pressure (MDP), maximum voiding volume (MVV), number of leakages per 24 h (L24), lower urinary tract symptoms (LUTS) score, and spinal cord injury-quality of life (SCI-QoL)score in patients with NLUTD after SCI were included.

View Article and Find Full Text PDF

Aim: To investigate the clinical efficacy of transurethral columnar balloon dilation of prostate (TUCBDP) in the treatment of small-volume benign prostatic hyperplasia (BPH) and provide the optimal treatment for the surgical treatment of small volume benign prostatic hyperplasia.

Methods: This retrospective study analyzed 106 patients with small-volume BPH who underwent surgical treatment at the Department of Urology, Xiangya Changde Hospital from December 2023 to January 2024. The patients were divided into two groups based on the type of surgery received: TUCBDP group (n = 53) and transurethral resection of prostate (TURP) group (n = 53), which serves as the control group.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!